Literature DB >> 19328037

DNA microarray analysis for the identification of innate immune pathways implicated in virus-induced autoimmune diabetes.

Travis R Wolter1, Randall Wong, Suparna A Sarkar, Danny Zipris.   

Abstract

We have recently demonstrated that upregulation of the innate immune system plays a key role in KRV-induced autoimmune diabetes in the BBDR rat, but the nature of this proinflammatory reaction has not yet been addressed. Using a DNA microarray approach, we identified 569 genes upregulated in pancreatic lymph nodes following virus infection. Among the most highly activated are IL-1 pathways, IFN-gamma-induced chemokines, and genes associated with interferon production and signaling. Ex vivo and in vitro studies indicate that KRV upregulates proinflammatory cytokines and chemokines in B lymphocytes and Flt-3L-induced plasmacytoid DCs (pDCs). Finally, in contrast to KRV, infection of BBDR rats with the non-diabetogenic KRV homologue H-1 parvovirus fails to induce a robust proinflammatory response in pancreatic lymph nodes. Our findings provide new insights into KRV-induced innate immune pathways that may play a role in early mechanisms leading to islet inflammation and diabetes.

Entities:  

Mesh:

Year:  2009        PMID: 19328037     DOI: 10.1016/j.clim.2009.02.007

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  14 in total

Review 1.  Targeting Innate Immunity for Type 1 Diabetes Prevention.

Authors:  James C Needell; Danny Zipris
Journal:  Curr Diab Rep       Date:  2017-09-27       Impact factor: 4.810

2.  Dysregulated Toll-like receptor-induced interleukin-1β and interleukin-6 responses in subjects at risk for the development of type 1 diabetes.

Authors:  Aimon K Alkanani; Marian Rewers; Fran Dong; Kathleen Waugh; Peter A Gottlieb; Danny Zipris
Journal:  Diabetes       Date:  2012-06-29       Impact factor: 9.461

Review 3.  The role of innate immune pathways in type 1 diabetes pathogenesis.

Authors:  Steven C Pino; Annie J Kruger; Rita Bortell
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2010-04       Impact factor: 3.243

4.  α1-Antitrypsin therapy downregulates toll-like receptor-induced IL-1β responses in monocytes and myeloid dendritic cells and may improve islet function in recently diagnosed patients with type 1 diabetes.

Authors:  Peter A Gottlieb; Aimon K Alkanani; Aaron W Michels; Eli C Lewis; Leland Shapiro; Charles A Dinarello; Danny Zipris
Journal:  J Clin Endocrinol Metab       Date:  2014-02-14       Impact factor: 5.958

Review 5.  The Role of the Intestinal Microbiome in Type 1 Diabetes Pathogenesis.

Authors:  James C Needell; Danny Zipris
Journal:  Curr Diab Rep       Date:  2016-10       Impact factor: 4.810

6.  Histone deacetylase inhibitor suppresses virus-induced proinflammatory responses and type 1 diabetes.

Authors:  Naoko Hara; Aimon K Alkanani; Charles A Dinarello; Danny Zipris
Journal:  J Mol Med (Berl)       Date:  2013-08-28       Impact factor: 4.599

7.  When the human viral infectome and diseasome networks collide: towards a systems biology platform for the aetiology of human diseases.

Authors:  Vincent Navratil; Benoit de Chassey; Chantal Rabourdin Combe; Vincent Lotteau
Journal:  BMC Syst Biol       Date:  2011-01-21

8.  Salicylate prevents virus-induced type 1 diabetes in the BBDR rat.

Authors:  Chaoxing Yang; Agata Jurczyk; Philip diIorio; Elaine Norowski; Michael A Brehm; Christian W Grant; Dennis L Guberski; Dale L Greiner; Rita Bortell
Journal:  PLoS One       Date:  2013-10-16       Impact factor: 3.240

Review 9.  Potential viral pathogenic mechanism in human type 1 diabetes.

Authors:  Darius A Schneider; Matthias G von Herrath
Journal:  Diabetologia       Date:  2014-07-30       Impact factor: 10.122

10.  Maternal treatment with short-chain fatty acids modulates the intestinal microbiota and immunity and ameliorates type 1 diabetes in the offspring.

Authors:  James C Needell; Diana Ir; Charles E Robertson; Miranda E Kroehl; Daniel N Frank; Danny Zipris
Journal:  PLoS One       Date:  2017-09-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.